Isleworth Healthcare Acquisition Corp
Isleworth Healthcare Acquisition — SPAC Merger (June 2022)
34 slides from Isleworth Healthcare Acquisition's SPAC merger presentation, Jun 6, 2022
Slide 1: BTIG China Biotech Day
BTIG China Biotech Day June 1st, 2022 Exhibit 99.1
Slide 2: Disclaimers
Disclaimer Disclaimers This Presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such in whi
Slide 3: Disclaimer: Use of Projections
Disclaimer Use of Projections This Presentation contains projected financial information with respect to Cytovia. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of futur
Slide 4: Genesis of Cytovia in the Context of the Revolution in Cell Therapy Oncology Therapies
Genesis of Cytovia in the Context of the Revolution in Cell Therapy Oncology Therapies ALL: Acute lymphoblastic leukemia To our knowledge 2012: Nobel Prize awarded for the discovery of iPSC cells 2020: First publication about CAR-NK in clinic in NEJM (MD Anderson)(2) 2020: Nobel Prize awarded for CR
Slide 5: Cytovia is a Next-generation Biotech Company at the Forefront of the NK Revolution
Cytovia is a Next-generation Biotech Company at the Forefront of the NK Revolution Towards a Cancer Cure First-in-class company combining gene-edited iPSC NK Cell and NK Cell-engager antibody platforms Exclusive or non-exclusive as to select targets Strong Management Team With Key Academic Partnersh
Slide 6: Premier Partnerships Providing Access to Core Technologies For Next Generation NK Cell Therapeutics
Premier Partnerships Providing Access to Core Technologies For Next Generation NK Cell Therapeutics cGMP Cell Manufacturing(3) Puerto Rico Research & Development Natick, MA The Cellectis $20MM convertible notes will convert into equity upon consummation of the Proposed Business Combination. The warr
Slide 7: Cytovia's Proprietary, In-House iPSC-Derived NK Cell and NK-Engager Platforms
Confidential Cytovia’s Proprietary, In-House iPSC-Derived NK Cell and NK-Engager Platforms Enabling Differentiated Therapies Across Multiple Indications Next-generation bispecific antibodies with: Proprietary quadrivalent, multifunctional format for enhanced efficiency Flexible linker that facilitat
Slide 8: FLEX-NK as Monotherapy or in Combinations With iNK Cells
iNK cells ready for infusion Combination therapy of FLEX-NKTM cell engagers and iNK cells in patients with impaired NK status Cytovia’s novel approach: FLEX-NKTM as Monotherapy or in Combinations With iNK Cells Flex-NKTM engager Endogeneous NK cell Monotherapy with FLEX-NKTM in patients with good NK
Slide 9: Cytovia Pipeline and Target IND Filing
Cytovia Pipeline and Target IND Filing(1) Platform Target Program Indication Pre-Clinical Clinical Next Milestone IND Filings Flex-NKTM Engager GPC3 CYT-303 HCC 2H 2022 CD38 CYT-338 MM 2H 2023 iNK Cell N/A CYT-100 HCC 1H 2023 N/A CYT-150 HCC, MM 2H 2023 GPC3 CYT-503 HCC 1H 2024 CD38 CYT-538 MM 1H 20
Slide 10: Cytovia's US-Based R&D and cGMP Cell Manufacturing Facility
Cytovia’s US-Based R&D and cGMP Cell Manufacturing Facility R&D FACILITY AND TEAM IN NATICK, MASSACHUSETTS DESIGNED FOR PRE-CLINICAL DEVELOPMENT AND CELL THERAPY PROCESS DEVELOPMENT Capabilities include: NK biological research iNK Cell process development Gene-editing in vitro and in vivo pharmacolo
Slide 11: China Market Access via CytoLynx Strategic Collaboration
Facilitates patient access and accelerates global development of GPC3 program China Market Access via CytoLynx Strategic Collaboration Shanghai development and fully operational manufacturing hub with local management team 1 Coordination with Cytovia on integrated development through Joint Developme
Slide 12: Glypican (GPC3) Hepatocellular Carcinoma Program
Glypican 3 (GPC3) Hepatocellular Carcinoma Program
Slide 13: Blue Ocean Opportunity for HCC
Blue Ocean Opportunity for HCC Market Data refers to small molecule therapies Source: Evaluate Pharma; Int. Agency for Research on Cancer from WHO, 2020; N Engl J Med 2019;380:1450-62. DOI: 10.1056/NEJMra1713263; N Engl J Med 2020;382:1894-905. DOI: 10.1056/NEJMoa1915745; J Res Med Sci. 2019; 24: 86
Slide 14: Cytovia's GPC3 Lead Program Aims to Develop First-in-Class HCC Therapies
Cytovia’s GPC3 Lead Program Aims to Develop First-in-Class HCC Therapies Cytovia’s GPC3 Program is Well Positioned to Address the Unmet Needs in HCC GPC3 Flex-NKTM + iNK Cells GPC3 CAR-iNK Cells GPC3 binder licensed from NCI hYP7 GPC3 CAR validation in vivo iNK demonstrated activity against HCC tumo
Slide 15: HCC: Attractive Market Opportunity with High Scarcity Value for GPC3-Targeting Therapies
HCC: Attractive Market Opportunity with High Scarcity Value for GPC3-Targeting Therapies Athenex acquired Kuur Therapeutics in May, 2021 Source: Baumhoer et al., Am J Clin Pathol 2008;129:899-906 Stage Phase 1 Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical Pre-Clinical Cell Type CA
Slide 16: GPC3 Flex-NK Cell Engagers Shown to Redirect NK Cells to Kill HCC Tumors Cells
GPC3 Flex-NKTM Cell Engagers Shown to Redirect NK Cells to Kill HCC Tumors Cells in vitro CYT-303 in combination with NK Cells demonstrated anti-tumor activity in vitro with a good safety profile Source: Arulandam et al, AACR, poster 2752 AACR 2022 CYT-303 showed cytotoxic activation of NK Cells aga
Slide 17: Cytovia's Unedited iNK Cells Demonstrated in vitro & in vivo Cytotoxicity
Cytovia’s Unedited iNK Cells Demonstrated in vitro & in vivo Cytotoxicity Source: Arulandam et al, AACR, poster 2752 AACR 2022 Cytotoxic Activity in vitro Anti-tumor Activity in vivo iNK Cells Demonstrated the Ability to Inhibit HepG2 Tumor Growth iNK Cells Shown to Potently Kill K562 Tumor Targets
Slide 18: Combination of CYT-303 and iNKs Showed Greater Hep3B Tumor Growth Inhibition
The Combination of CYT-303 and iNKs Showed Greater Hep3B Tumor Growth Inhibition Compared to iNKs Alone In an in vivo Model of Hepatocellular Carcinoma (HCC) Proof-of-concept of CYT-303 and iNK combination in vivo presented at AACR 2022 Functional Activities in vivo Source: Arulandam et al, AACR, po
Slide 19: HCC-Specific Multi-Cohort Phase 1/2 Study Design
HCC-Specific Multi-Cohort Phase 1/2 Study Design Trials designed to evaluate monotherapy and combinations Dose expansion Phase 1 CYT-303 Dose Escalation Arm A DL1 DLx RP2D Mono CYT-303 RP2D CYT-100 Dose Escalation Arm B CYT-303 + CYT-100 Combo Arm C DL1 DLx RP2D Mono CYT-100 RP2D Combo RP2D CYT-303
Slide 20: Broader Pipeline: Multiple Myeloma and Glioblastoma Programs
Broader Pipeline Multiple Myeloma and Glioblastoma Programs
Slide 21: CD38 NKp46 FLEX-NK Engagers Target and Kill Multiple Myeloma Cells
Cytovia's Novel Multifunctional Tetravalent CD38 NKp46 FLEX-NKTM Engagers Actively Target and Kill Multiple Myeloma Cells While Sparing Immune Cells CD38 is a clinically and commercially validated target providing a balanced risk profile to Cytovia’s pipeline Source: Evaluate Pharma; Arulandam et al
Slide 22: Intracranial EGFR Dual Targeting CAR-NK Improves Survival in Glioblastoma Model
Intracranial EGFR Dual Targeting CAR-NK Shown to Improve Survival in in vivo Model of Glioblastoma Cytovia’s CYT-501 is a potential first-in-class iPSC CAR-iNK product to target both wtEGFR & EGFR vIII Source: Yan, Caligiuri, Yu et al, Sci Rep. 2015 Yu, Caligiuri, et al, 2020. c Michael Caligiuri, M
Slide 23: Cytovia Therapeutics: Platform Technologies and Manufacturing
Cytovia Therapeutics: Platform Technologies and Manufacturing
Slide 24: Target Product Profile: iPSC Technology Benefits Over Existing Cell Therapy Approaches
Target Product Profile Autologous CAR-T Allogeneic CAR-T Donor-Derived CAR-NK(2) iPSC-Derived CAR-NK EXPECTED SAFETY Graft Versus Host Disease Risk (GvHD) Low TBD Low Low Cytokine Release Syndrome (CRS) or Neurotoxicity Risk High High Low Low MANUFACTURING Off-the-Shelf Product - + + ++ Cost of Manu
Slide 25: Fully-Integrated In-House Process Development and cGMP Manufacturing for iNK Platform
GPC3: Dr. Ho/NCI EGFR: Dr. Caligiuri/Cytoimmune CD38: Dr. Bensussan/INSERM Dr. Eyquem/UCSF TALEN® / Cellectis Cytovia Has a Fully-Integrated, In-House Process Development and cGMP Manufacturing Capabilities for iNK Cell Platform(1) Puerto Rico-based cGMP manufacturing facility expected to be operati
Slide 26: TALEN Gene-Edited iNK and CAR-iNK Cells
TALEN® Gene-Edited iNK and CAR-iNK Cells TALEN® Gene-Edited iNK Cells for Augmenting Persistence and Performance of NK Cells Cellectis’ proprietary gene targeting method to edit cells - cutting DNA at the optimal locus and repairing it to knock-in and knock-out desired edits TALEN® Gene-Editing Expe
Slide 27: Cytovia-UCSF Collaboration to Identify Optimal Loci for Gene-Editing
Cytovia-UCSF Collaboration Designed to Identify Optimal Loci for Gene-Editing Seeking to develop next-generation CAR-NK Cells with improved tumor killing activity, persistence and therapeutic activity as well as more standardized manufacturing Gene targeting of optimally designed CAR in NK Cells AIM
Slide 28: NK-Cell Engager Platform: Proprietary BsAb Technology
NK-Cell Engager Platform: Proprietary BsAb Technology to Redirect and Further Activate NK cells Flex-NKTM Cell Engager multi-specific antibodies help redirect NK Cells towards their target and further activate their killing activity at the tumor site Data on file Source: Golay et al. J. Immunol 2016
Slide 29: Cytovia's Differentiated Approach to Engage NK Cells
Cytovia’s Differentiated Approach to Engage NK Cells Primary driver of NK Cell’s “natural cytotoxicity” Mediates NK Cell lysis of autologous, allogeneic or xenogeneic cells NKp46 shows sustained expression on NK Cells in the tumor microenvironment while other activating receptors, such as NKG2D, NKp
Slide 30: Multiple Anticipated Near-term Value Inflection Points
Multiple Anticipated Near-term Value Inflection Points 1H ‘22 2H ‘23 2H ‘22 1H ‘23 Initial pre-clinical data for iNKs + Flex-NKTM Cell Engagers Preliminary Phase 1 data of CYT-303 and CYT-100 Complete IND enabling studies of CYT-150 and CYT-338 File INDs for CYT-150 and CYT-338 Proof-of-concept of g
Slide 31: Key Investment Considerations
Key Investment Considerations First-in-class GPC3-targeting program for HCC with in vivo proof-of-concept and initial INDs expected in 2022 and 2023 1 First company to combine proprietary NK Cell engager antibodies & iPSC-derived NK Cells 2 Integrated R&D and cGMP cell manufacturing led by entrepren
Slide 32: Risk Factors: Certain Risks Related to Cytovia Holdings, Inc.
Risk Factors Certain Risks Related to Cytovia Holdings, Inc. The below list of key risks has been prepared for the purposes of the proposed private placement transaction (the “Private Placement”) as part of the Proposed Business Combination, and for potential investors in the Private Placement. Unle
Slide 33: Risk Factors: Manufacturing and Dependence on Third Parties
Risk Factors (cont’d) Risks Related to Manufacturing and Cytovia’s Dependence on Third Parties Cytovia has established manufacturing facilities for the production of its product candidates and other future products. As an organization, Cytovia has limited experience in the construction of a manufact
Slide 34: Risk Factors: Regulation and Legal Compliance
Risk Factors (cont’d) Risks Related to Regulation and Legal Compliance29 Even if Cytovia obtains regulatory approvals for its product candidates, they will remain subject to ongoing regulatory oversight. The regulatory processes that will govern the approval of Cytovia’s product candidates are compl
Isleworth Healthcare Acquisition — SPAC Merger (June 2022) on 6ix